Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Horvat

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
The Annals of Pharmacotherapy|October 14, 2017
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic LeukemiaTroy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, et al.
Journal of Clinical & Laboratory Immunology|May 1, 1991
T cell subset composition in remission phase of systemic connective tissue diseasesJ Markeljević, M Marusić, B Uzarević, et al.
Medicinski Pregled|January 1, 1987
[Kidney transplantation (concept, organization and initial results)]S Avramov, M Fabri, Z Horvat, et al.
Leukemia Research|September 16, 2016
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intoleranceTroy Z Horvat, Joshua J Pecoraro, Ryan J Daley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
The Annals of Pharmacotherapy|October 14, 2017
The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic LeukemiaTroy Z Horvat, Amanda N Seddon, Adebayo Ogunniyi, et al.
Journal of Clinical & Laboratory Immunology|May 1, 1991
T cell subset composition in remission phase of systemic connective tissue diseasesJ Markeljević, M Marusić, B Uzarević, et al.
Medicinski Pregled|January 1, 1987
[Kidney transplantation (concept, organization and initial results)]S Avramov, M Fabri, Z Horvat, et al.
Leukemia Research|September 16, 2016
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intoleranceTroy Z Horvat, Joshua J Pecoraro, Ryan J Daley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2016
Reply to A. Indini et alTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.
Blood Advances|March 9, 2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AMLMaximilian Stahl, Kamal Menghrajani, Andriy Derkach, et al.
Pageof 5